Related Experiment Video
Updated: Sep 21, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Experimental immunotherapy of mice with transplanted MC-rhabdomyosarcoma resistant to doxorubicin
Ninel M Berezhnaya1, Elena V Kovalchuk, Yulya D Vinnichuk
1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine. berezh@onconet.kiev.ua
Aim:
To compare the sensitivity of doxorubicin (DOX) sensitive and DOX-resistant MC-rhabdomyosarcoma (MC-RMS) cells to the action of lymphokine-activated cells (LAC).
Results:
In vitro investigations showed that LAC received from the fraction of adherent lymphocytes possess the highest activity against DOX-resistant tumor cells, and LAC from lymphocytes of total pool--against DOX-resistant tumor cells pretreated with DOX at a low dose. Adoptive immunotherapy of MC-RMS in vivo showed the highest efficacy in the cases of LAC intratumoral injection and the one combined with intraperitoneal administration of DOX at a low dose (increase of survival time by 14% and 25%, respectively).
Conclusion:
Adoptive in vivo therapy of DOX-resistant Mh-RMS is effective if LAC or their combination with DOX at a low dose are administered.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023